Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Infant visual acuity

This article was originally published in The Tan Sheet

Executive Summary

Infants fed formula containing docosahexaenoic acid (DHA) and arachidonic acid (AA) "showed acuity maturation similar to that of the human milk-fed group throughout the first year of life" in a study of 108 healthy term infants published in the August issue of Pediatric Research. The study, by Eileen Birch et al., concludes "early dietary intake of preformed DHA and AA appears necessary for optimal development of the brain and eye of the human infant." The DHA and AA were supplied by Columbia, Md.-based Martek. The company maintains the study "is the first to show a persistent effect in visual acuity development related to dietary intake of DHA." A grant from NIH funded the study while Mead Johnson provided the formula and supplementary funding...

You may also be interested in...



Similac Superiority Claims Over Enfamil Should Be Modified – NAD

Marketing claims that Similac and SimilacAdvance are "'the best' and superior to Enfamil and Enfamil Lipil in terms of a baby's mental development and visual acuity" should be discontinued, the National Advertising Division says in a recent decision

Similac Superiority Claims Over Enfamil Should Be Modified – NAD

Marketing claims that Similac and SimilacAdvance are "'the best' and superior to Enfamil and Enfamil Lipil in terms of a baby's mental development and visual acuity" should be discontinued, the National Advertising Division says in a recent decision

Similac Superiority Claims Over Enfamil Should Be Modified – NAD

Marketing claims that Similac and SimilacAdvance are "'the best' and superior to Enfamil and Enfamil Lipil in terms of a baby's mental development and visual acuity" should be discontinued, the National Advertising Division says in a recent decision

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088760

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel